Updates are available Correction dated 2025-04-25
Click to view Correction: https://doi.org/10.1007/s11606-025-09417-6
-
Authors
Xu, Yunwen
Boyle, Thomas A.
Lyu, Beini
Ballew, Shoshana H.
Selvin, Elizabeth
Chang, Alexander R.
Inker, Lesley A.
Grams, Morgan E.
Shin, Jung-Im https://orcid.org/0000-0003-0374-6927
- License Information
-
More Information
Article History
Received: 14 August 2023
Accepted: 22 December 2023
First Online: 8 January 2024
Change Date: 25 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11606-025-09417-6
Declarations:
:
: A. Chang reports having consultancy agreements with Amgen, Novartis, and Reata; reports receiving research funding from a Novo Nordisk Investigator Sponsored Study; reports having an advisory or leadership role with Reata, Relypsa; and reports having other interests or relationships with National Kidney Foundation grant support and the NKF Patient Network. E. Selvin reports receiving research support from the Foundation for the National Institutes of Health and the National Institutes of Health; reports receiving royalty payments from Wolters Kluwer for chapters and laboratory monographs in UpToDate on measurements of glycemic control and screening tests for type 2 diabetes; and reports having an advisory or leadership role with Diabetes Care and Diabetologia Editorial Board, the American Diabetes Association, and the American Heart Association. L. Inker reports having consultancy agreements with Diamtrix; reports receiving research funding to the institution for research and contracts with the National Institutes of Health, National Kidney Foundation, Omeros, Reata Pharmaceuticals; reports having consulting agreements to her institution with Omeros and Tricida Inc.; reports having an advisory or leadership role with the Alport Syndrome Foundation; and reports having other interests or relationships as a member of the American Society of Nephrology, the National Kidney Disease Education Program, and the National Kidney Foundation. M. Grams reports having an advisory or leadership role with AJKD, CJASN, JASN Editorial Board, KDIGO Executive Committee, NKF Scientific Advisory Board, and the USRDS Scientific Advisory Board; and reports having other interests or relationships with grant funding from NKF, which receives funding from multiple pharmaceutical companies, and grant funding from the National Institutes of Health. J. Shin reports receiving research funding from Merck and the National Institutes of Health. The remaining authors have nothing to disclose.
